• Vascular biology for clinical practice: From basic concepts to mainstream medicine
Physicians who participated at recent Vascular Biology Working Group meetings have provided the direction for the development of these materials.
The program offers a comprehensive update of studies that are advancing our understanding of vascular pathobiology and providing new evidence-based treatment approaches for cardiovascular risk reduction.
The information in this slide/lecture program has two primary areas of focus:
- An update on basic science advances in vascular biology and how this new data may be driving the results of new clinical trials
- New clinical trials that have shown that treatment directed to the underlying vascular pathobiology translates into improved clinical outcomes.
This program updates and extends the knowledge presented in the first two volumes of this series and other VBWG programs, and reflects the continued advance of vascular biology into mainstream medicine.
A major focus of this program is on clinical practice issues related to prevention and cardiovascular risk reduction. Emphasis is on management strategies that 1) consider multiple risk factors, 2) employ evidence-based medicine, and 3) use adequate dosing and combination therapies to enhance clinical outcomes. The recent HOPE study, which demonstrates an expanded role for ACE inhibition in high-risk patients to achieve vasculoprotective benefits beyond blood pressure lowering, is discussed, along with new data that demonstrate the benefit of aggressive lipid lowering to reduce cardiovascular risk.
Cardiovascular disease: Leading cause of death
Download 01CoreS01.ppt (11 slides - 0.4MB)
The progression from CV risk factors to endothelial injury and clinical events
Download 01CoreS02.ppt (11 slides - 0.7MB)
Section III: The renin-angiotensin system and ACE inhibition
Download 01CoreS03.ppt (12 slides - 0.5MB)
Section IV: The interaction of the RAS and lipids
Download 01CoreS04.ppt (9 slides - 0.4MB)
Section V: Improving outcomes in CAD: Trial updates
Download 01CoreS05.ppt (62 slides - 2.6MB)
Section VI: Lipids: New insights into the importance of aggressive treatment
Download 01CoreS06.ppt (59 slides - 2.5MB)
Section VII: Diabetes and the impact of risk factor clustering on CV risk
Download 01CoreS07.ppt (28 slides - 1.2MB)
Section VIII: Heart failure:
Download 01CoreS08.ppt (26 slides - 1.2MB)
Published by Medical Education Consultants, Inc. (MEDCON), on behalf of the University of Florida College of Medicine.
The editorial content of this program does not necessarily reflect the views or recommendations of the University of Florida College of Medicine, Wyeth-Ayerst Laboratories, Monarch Pharmaceuticals, Pfizer Inc, or the publisher. The reader is advised to consult the full prescribing information of each product prior
This program was prepared and produced by Medical Education Consultants, Inc., Westport, Connecticut, on behalf of the University of Florida College of Medicine through an unrestricted educational grant provided by Wyeth-Ayerst Laboratories, Monarch Pharmaceuticals, and Pfizer Inc.
©2001 Medical Education Consultants, Inc. (MEDCON). All rights reserved.